New Key Statistics Module, Z-Score and F-Score
NAS:ALLO Key Ratios
| Market Cap $ M | 438.21 |
| Enterprise Value $ M | 231.79 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 0.94 |
| Price/Sales | 2,090.00 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -1.56 |
| Beneish M-Score | -1.61 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 17.40 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -0.74 |
| EV-to-EBITDA | -0.77 |
| PEG | -- |
| Shares Outstanding M | 209.67 |
| Net Margin (%) | -659,137.21 |
| Operating Margin % | -625,246.51 |
| Pre-tax Margin (%) | -659,137.21 |
| Quick Ratio | 9.35 |
| Current Ratio | 9.35 |
| ROA % (ttm) | -44.60 |
| ROE % (ttm) | -55.89 |
| ROIC % (ttm) | -121.34 |
| Dividend Yield % | -- |
| Altman Z-Score | -3.12 |
ALLO Number of Guru Trades
ALLO Volume of Guru Trades
Gurus Latest Trades with NAS:ALLO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:ALLO is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Allogene Therapeutics Inc Insider Transactions
No Available Data
News about NAS:ALLO
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers